PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
Sentynl Therapeutics, Inc.
 

Company Overview

Products & Services

Contact Info & Offices

Press Releases

Executives & Employees

Image Gallery

Sentynl Therapeutics, Inc.

Press Release


Receive press releases from Sentynl Therapeutics, Inc.: By Email RSS Feeds:

Sentynl Therapeutics, Inc. Welcomes Darren Pincus as Vice President of Business Development


Solana Beach, CA, May 01, 2016 --(PR.com)-- Sentynl Therapeutics, Inc. (“Sentynl”) announced that Darren Pincus joined Sentynl as its Vice President and head of Business Development. Mr. Pincus is a highly experienced business development professional with a strong track record of successfully completed transactions.

Prior to Sentynl, Mr. Pincus was Executive Director of Corporate and Business Development at Pacira Pharmaceuticals, where he was responsible for in-licensing, international out-licensing and pipeline initiatives. Previously, Mr. Pincus was Vice President of Corporate Development for EKR Therapeutics where he led the Corporate Development function. Prior to EKR, Mr. Pincus served in senior business development roles at Alpharma, Savient Pharma, and PLIVA / Odyssey Pharma. Mr. Pincus began his career in the Global Healthcare Corporate Finance practice of Arthur Anderson. Mr. Pincus earned his B.S. in Finance from the Pennsylvania State University.

About Sentynl Therapeutics.
Sentynl provides healthcare professionals with treatment solutions that enable them to meet the needs of individual patients. Sentynl’s highly experienced and knowledgeable management team has previously built multiple successful pharmaceutical companies.

With a focus on commercialization, Sentynl looks to source effective and well-differentiated products across a broad spectrum of therapeutic areas. Sentynl is committed to the highest ethical standards and compliance with all applicable laws, regulations, and industry guidelines.

In order to complement its existing product portfolio and further leverage its commercial infrastructure, Sentynl currently seeks product licensing and acquisition opportunities. Target acquisition opportunities include late stage development programs and marketed products in specialty pharmaceuticals.

For more information about Sentynl, please visit http://www.sentynl.com/.
Contact Information
Sentynl Therapeutics, Inc.
Whitney Nelsen
888-227-8725
Contact
www.sentynl.com/

Click here to view the company profile of Sentynl Therapeutics, Inc.
Click here to view the list of recent Press Releases from Sentynl Therapeutics, Inc.
Promote Your Business